KRAS Status Doesn't Impact Treatment with 5-FU Alone

While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs?

5-FU (fluorouracil) is the backbone of most colorectal cancer treatment, given alone or in combination with other drugs.  What does KRAS status mean when 5-FU is the only treatment?

To see whether or not, KRAS mutation status affected outcome of 5-FU treatment, researchers analyzed tumor tissue from patients who had 5-FU treatment only.  Patients in the study had cancer that had spread to their liver (liver metastases), and the liver mets could not be surgically removed.

They found:

  • 38.7 percent of the patients had a KRAS mutation in their tumors.
  • KRAS mutations in liver tumors matched exactly with those in primary tumors in the colon.
  • There was no significant difference in the percentage of liver tumors that got smaller with 5-FU treatment (objective response rate).
  • There was no difference in survival between the group of patients with mutated KRAS and those with normal or wild-type KRAS.

Marie-Christine Etienne-Grimaldi and her French colleagues concluded,

The present data indicate a perfect concordance of K-Ras mutations between primary and liver metastasis and suggest that any predictive and/or prognostic value of K-Ras mutations in treatments combining anti-EGFR monoclonal antibodies with 5-FU should be exclusively linked to the anti-EGFR agent.

Other research has found that Avastin®(bevacizumab) treatment outcomes are not affected by KRAS status.

SOURCE:Etienne-Grimaldi et al.,Clinical Cancer Research, Volume 14, Number 15, August 1, 2008.

Share on FacebookTweet about this on TwitterPin on PinterestShare on Google+Email this to someone

Leave a Reply